Identification | Back Directory | [Name]
COR 170 | [CAS]
1048039-15-1 | [Synonyms]
COR 170 N-(Adamant-1-yl)-4-oxo-1-pentyl-6-phenyl-1,4-dihydroquinoline-3-carboxamide 3-Quinolinecarboxamide, 1,4-dihydro-4-oxo-1-pentyl-6-phenyl-N-tricyclo[3.3.1.13,7]dec-1-yl- | [Molecular Formula]
C31H36N2O2 | [MDL Number]
MFCD27991277 | [MOL File]
1048039-15-1.mol | [Molecular Weight]
468.63 |
Hazard Information | Back Directory | [Description]
Selective inverse agonist of CB2 receptors (Ki values are 3.8 and >10,000 nM for CB2 and CB1, respectively). | [Uses]
COR170 (11u) is a selective CB2 inverse-agonist which is a 4-quinolone-3-carboxylic acid derivative with a Ki value of 3.8 nM for CB2 receptor. COR170 can be used for the research of inflammation and neuroprotection[1][2][3]. | [in vivo]
COR170 (11u) (1.5-6 mg/kg; i.p, once) reduces the late phase nociceptive behaviour induced by formalin[3]. Animal Model: | Mice with formalin (1.25%, 30 μL) injections[3] | Dosage: | 1.5, 3 and 6 mg/kg | Administration: | Intraperitoneal injection; 1.5, 3 and 6 mg/kg for once | Result: | Reduced the late phase nociceptive behaviour induced by formalin with a 6 mg/kg dose and 10 min before formalin and abolished the analgesic effect from GW405833 which is a CB2 receptor partial agonist. |
| [storage]
Store at RT | [References]
[1] Contartese A, et al. A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury. Pharmacol Res. 2012 Dec;66(6):555-63. DOI:10.1016/j.phrs.2012.08.003 [2] Pasquini S, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J Med Chem. 2008 Aug 28;51(16): DOI:10.1021/jm800552f [3] Cascio MG, et al. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. Pharmacol Res. 2010 Apr;61(4):349-54. DOI:10.1016/j.phrs.2009.11.011 |
|
Company Name: |
BOC Sciences
|
Tel: |
|
Website: |
https://www.bocsci.com |
|